SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) closed an underwritten public offering of ordinary shares, raising $57.5 million in gross proceeds before fees and expenses. The company sold 12,104,900 shares at $4.75 each, including 1,578,900 additional shares from the underwriters’ fully exercised option, with all shares sold by the company.

Positive

• Gross proceeds of $57.5 million from public equity offering
• Underwriters fully exercised 1,578,900-share option due to demand
• All 12,104,900 shares sold at a fixed price of $4.75

Negative

• Issuance of 12,104,900 new shares likely increases share count and dilution

Market Context

This announcement confirms closing of a fully subscribed equity raise with $57.5 million in gross pr...

Analysis

This announcement confirms closing of a fully subscribed equity raise with $57.5 million in gross proceeds and full underwriter option exercise. Investors may track use of cash, the active F-3 shelf, and relatively low short interest as key risk and support factors.

Key Figures

Gross proceeds: $57.5 million Additional shares option: 1,578,900 shares Total shares sold: 12,104,900 shares +3 more

6 metrics

Gross proceeds $57.5 million Total gross proceeds from the underwritten public offering before fees

Additional shares option 1,578,900 shares Underwriters’ option to purchase additional ordinary shares, fully exercised

Total shares sold 12,104,900 shares Total ordinary shares sold in the offering, including option shares

Offering price $4.75 per share Public offering price for the ordinary shares

Form F-3 file number File No. 333-289266 SEC registration statement covering this and other securities

F-3 effectiveness date August 15, 2025 Date the Form F-3 registration statement was declared effective

Previous Offering Reports

2 past events · Latest: Jun 16 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 16	Equity offering pricing	Negative	+6.3%	Public offering priced with significant capital raise and underwriter option disclosed.
Jun 16	Equity offering launch	Negative	+6.3%	Company announced proposed underwritten share sale and potential 15% underwriter option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent equity offering announcements have triggered notably positive price reactions, suggesting investors have previously welcomed SOPH’s capital-raising news.

Key Terms

underwritten public offering, form f-3, prospectus supplement, swiss financial services act

4 terms

underwritten public offering financial

"announced today the closing of its previously announced underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

form f-3 regulatory

"A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"The offering was made only by means of a prospectus supplement and accompanying prospectus."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

swiss financial services act regulatory

"within the meaning of the Swiss Financial Services Act ("FinSA") and these securities"

The Swiss Financial Services Act is a national law that sets rules for how banks, advisers and other firms must sell and explain investment products to clients in Switzerland. It requires clear disclosures, checks that products fit a client’s needs, and standardized documentation — like a consumer label and user manual for financial offers — so investors can compare choices and spot risks. For investors this means stronger protection, clearer information and more accountability from firms handling their money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares at the public offering price, less the underwriting discounts and commissions. The Company sold 12,104,900 ordinary shares at a price to the public of $4.75 per share, which included the 1,578,900 ordinary shares issued upon exercise in full by the underwriters of their option to purchase additional shares. All of the ordinary shares were sold by the Company.

TD Cowen acted as the lead book-running manager for the offering. Guggenheim Securities acted as book-running manager, and BTIG and Craig-Hallum acted as lead managers for the offering.

A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares and other securities of the Company has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 15, 2025. The offering was made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus are available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, may be obtained for free by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of SOPHiA GENETICS SA, such as the ordinary shares, in or into Switzerland within the meaning of the Swiss Financial Services Act ("FinSA") and these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland. Neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, may be publicly distributed or otherwise made publicly available in Switzerland.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-closing-of-57-5-million-public-offering-of-ordinary-shares-with-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-302805285.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPHiA GENETICS (SOPH) announce on June 19, 2026 about its public offering?

SOPHiA GENETICS announced the closing of its underwritten public offering, raising gross proceeds of $57.5 million. According to SOPHiA GENETICS, all shares in the offering were sold by the company, increasing its equity capital before underwriting discounts, commissions, and offering expenses.

How many SOPHiA GENETICS (SOPH) shares were sold and at what price in the June 2026 offering?

The company sold 12,104,900 ordinary shares at a public offering price of $4.75 per share. According to SOPHiA GENETICS, this share count includes 1,578,900 additional shares issued when underwriters fully exercised their option to purchase more shares.

What was the size of the SOPHiA GENETICS (SOPH) equity raise in June 2026?

The equity raise generated total gross proceeds of $57.5 million before fees and expenses. According to SOPHiA GENETICS, this amount reflects the full underwritten public offering, including shares sold through the underwriters’ exercised option to purchase additional ordinary shares.

Did underwriters exercise their option to buy additional SOPHiA GENETICS (SOPH) shares?

Yes, underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares. According to SOPHiA GENETICS, these additional shares were sold at the same $4.75 public offering price, contributing to the total 12,104,900 shares issued in the transaction.

Which banks managed the June 2026 SOPHiA GENETICS (SOPH) public offering?

TD Cowen served as lead book-running manager, with Guggenheim Securities as book-running manager. According to SOPHiA GENETICS, BTIG and Craig-Hallum acted as lead managers for the offering, handling distribution of the newly issued ordinary shares to investors.

Where can investors find the SOPHiA GENETICS (SOPH) June 2026 offering prospectus?

Investors can access the final prospectus supplement and prospectus via the SEC’s website at www.sec.gov. According to SOPHiA GENETICS, printed copies may also be requested for free from TD Securities (USA) LLC through Broadridge Financial Solutions or its dedicated email contact.

Is the SOPHiA GENETICS (SOPH) share offering available to the public in Switzerland?

No, the share offering is not intended as a public offer in Switzerland under FinSA. According to SOPHiA GENETICS, the securities will not be listed on SIX Swiss Exchange, and related materials may not be publicly distributed or made publicly available in Switzerland.